|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Qiu ZX, Sun RF, Mo XM and Li WM: The
p70S6K specific inhibitor PF-4708671 impedes non-small cell lung
cancer growth. PLoS One. 11:e01471852016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang C, Zhang H, Shi J, Wang D, Zhang X,
Yang J, Zhai Q and Ma A: Trial-based cost-utility analysis of
icotinib versus gefitinib as second-line therapy for advanced
non-small cell lung cancer in China. PLoS One. 11:e01518462016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Steeg PS: Metastasis suppressors alter the
signal transduction of cancer cells. Nat Rev Cancer. 3:55–63. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Houtkooper RH, Pirinen E and Auwerx J:
Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol
Cell Biol. 13:225–238. 2012.PubMed/NCBI
|
|
6
|
Bosch-Presegué L and Vaquero A: The dual
role of sirtuins in cancer. Genes Cancer. 2:648–662. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
North BJ and Verdin E: Sirtuins:
Sir2-related NAD-dependent protein deacetylases. Genome Biol.
5:2242004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Matsushima S and Sadoshima J: The role of
sirtuins in cardiac disease. Am J Physiol Heart Circ Physiol.
309:H1375–H1389. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Michishita E, Park JY, Burneskis JM,
Barrett JC and Horikawa I: Evolutionarily conserved and
nonconserved cellular localizations and functions of human SIRT
proteins. Mol Biol Cell. 16:4623–4635. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Meng X, Tan J, Li M, Song S, Miao Y and
Zhang Q: Sirt1: Role under the condition of ischemia/hypoxia. Cell
Mol Neurobiol. Mar 14–2016.Epub ahead of print. View Article : Google Scholar
|
|
11
|
Donmez G and Outeiro TF: SIRT1 and SIRT2:
Emerging targets in neurodegeneration. EMBO Mol Med. 5:344–352.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lombard DB, Alt FW, Cheng HL, Bunkenborg
J, Streeper RS, Mostoslavsky R, Kim J, Yancopoulos G, Valenzuela D,
Murphy A, et al: Mammalian Sir2 homolog SIRT3 regulates global
mitochondrial lysine acetylation. Mol Cell Biol. 27:8807–8814.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Onyango P, Celic I, McCaffery JM, Boeke JD
and Feinberg AP: SIRT3, a human SIR2 homologue, is an NAD-dependent
deacetylase localized to mitochondria. Proc Natl Acad Sci USA.
99:13653–13658. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nakagawa T, Lomb DJ, Haigis MC and
Guarente L: SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and
regulates the urea cycle. Cell. 137:560–570. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Haigis MC, Mostoslavsky R, Haigis KM,
Fahie K, Christodoulou DC, Murphy AJ, Valenzuela DM, Yancopoulos
GD, Karow M, Blander G, et al: SIRT4 inhibits glutamate
dehydrogenase and opposes the effects of calorie restriction in
pancreatic beta cells. Cell. 126:941–954. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mao Z, Hine C, Tian X, Van Meter M, Au M,
Vaidya A, Seluanov A and Gorbunova V: SIRT6 promotes DNA repair
under stress by activating PARP1. Science. 332:1443–1446. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
McCord RA, Michishita E, Hong T, Berber E,
Boxer LD, Kusumoto R, Guan S, Shi X, Gozani O, Burlingame AL, et
al: SIRT6 stabilizes DNA-dependent protein kinase at chromatin for
DNA double-strand break repair. Aging (Albany, NY). 1:109–121.
2009. View Article : Google Scholar
|
|
18
|
Kiran S, Anwar T, Kiran M and Ramakrishna
G: Sirtuin 7 in cell proliferation, stress and disease: Rise of the
seventh sirtuin! Cell Signal. 27:673–682. 2015. View Article : Google Scholar
|
|
19
|
Ford E, Voit R, Liszt G, Magin C, Grummt I
and Guarente L: Mammalian Sir2 homolog SIRT7 is an activator of RNA
polymerase I transcription. Genes Dev. 20:1075–1080. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Grob A, Roussel P, Wright JE, McStay B,
Hernandez-Verdun D and Sirri V: Involvement of SIRT7 in resumption
of rDNA transcription at the exit from mitosis. J Cell Sci.
122:489–498. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim JK, Noh JH, Jung KH, Eun JW, Bae HJ,
Kim MG, Chang YG, Shen Q, Park WS, Lee JY, et al: Sirtuin7
oncogenic potential in human hepatocellular carcinoma and its
regulation by the tumor suppressors MiR-125a-5p and MiR-125b.
Hepatology. 57:1055–1067. 2013. View Article : Google Scholar
|
|
22
|
Yu H, Ye W, Wu J, Meng X, Liu RY, Ying X,
Zhou Y, Wang H, Pan C and Huang W: Overexpression of sirt7 exhibits
oncogenic property and serves as a prognostic factor in colorectal
cancer. Clin Cancer Res. 20:3434–3445. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ebrahimi A and Sadroddiny E: MicroRNAs in
lung diseases: Recent findings and their pathophysiological
implications. Pulm Pharmacol Ther. 34:55–63. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mendell JT and Olson EN: MicroRNAs in
stress signaling and human disease. Cell. 148:1172–1187. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Winter J, Jung S, Keller S, Gregory RI and
Diederichs S: Many roads to maturity: microRNA biogenesis pathways
and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cortinovis D, Monica V, Pietrantonio F,
Ceresoli GL, La Spina CM and Wannesson L: MicroRNAs in non-small
cell lung cancer: Current status and future therapeutic promises.
Curr Pharm Des. 20:3982–3990. 2014. View Article : Google Scholar
|
|
28
|
Feng B, Zhang K, Wang R and Chen L:
Non-small-cell lung cancer and miRNAs: Novel biomarkers and
promising tools for treatment. Clin Sci (Lond). 128:619–634. 2015.
View Article : Google Scholar
|
|
29
|
Barger JF and Nana-Sinkam SP: MicroRNA as
tools and therapeutics in lung cancer. Respir Med. 109:803–812.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li L, Han LY, Yu M, Zhou Q, Xu JC and Li
P: Pituitary tumor-transforming gene 1 enhances metastases of
cervical cancer cells through miR-3666-regulated ZEB1. Tumour Biol.
2015:Sep 17–2015.Epub ahead of print.
|
|
31
|
Wang G, Cai C and Chen L: MicroRNA-3666
regulates thyroid carcinoma cell proliferation via MET. Cell
Physiol Biochem. 38:1030–1039. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Barber MF, Michishita-Kioi E, Xi Y,
Tasselli L, Kioi M, Moqtaderi Z, Tennen RI, Paredes S, Young NL,
Chen K, et al: SIRT7 links H3K18 deacetylation to maintenance of
oncogenic transformation. Nature. 487:114–118. 2012.PubMed/NCBI
|
|
33
|
Singh S, Kumar PU, Thakur S, Kiran S, Sen
B, Sharma S, Rao VV, Poongothai AR and Ramakrishna G:
Expression/localization patterns of sirtuins (SIRT1, SIRT2, and
SIRT7) during progression of cervical cancer and effects of sirtuin
inhibitors on growth of cervical cancer cells. Tumour Biol.
36:6159–6171. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang S, Chen P, Huang Z, Hu X, Chen M, Hu
S, Hu Y and Cai T: Sirt7 promotes gastric cancer growth and
inhibits apoptosis by epigenetically inhibiting miR-34a. Sci Rep.
5:97872015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang HL, Lu RQ, Xie SH, Zheng H, Wen XM,
Gao X and Guo L: SIRT7 exhibits oncogenic potential in human
ovarian cancer cells. Asian Pac J Cancer Prev. 16:3573–3577. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Aljada A, Saleh AM, Alkathiri M, Shamsa
HB, Al-Bawab A and Nasr A: Altered sirtuin 7 expression is
associated with early stage breast cancer. Breast Cancer (Auckl).
9:3–8. 2015.
|
|
37
|
Geng Q, Peng H, Chen F, Luo R and Li R:
High expression of Sirt7 served as a predictor of adverse outcome
in breast cancer. Int J Clin Exp Pathol. 8:1938–1945.
2015.PubMed/NCBI
|
|
38
|
McGlynn LM, McCluney S, Jamieson NB,
Thomson J, MacDonald AI, Oien K, Dickson EJ, Carter CR, McKay CJ
and Shiels PG: SIRT3 & SIRT7: Potential novel biomarkers for
determining outcome in pancreatic cancer patients. PLoS One.
10:e01313442015. View Article : Google Scholar :
|
|
39
|
Aljada A, Saleh AM and Al Suwaidan S:
Modulation of insulin/IGFs pathways by sirtuin-7 inhibition in
drug-induced chemoreistance. Diagn Pathol. 9:942014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhao L and Wang W: miR-125b suppresses the
proliferation of hepatocellular carcinoma cells by targeting
Sirtuin7. Int J Clin Exp Med. 8:18469–18475. 2015.
|
|
41
|
Han Y, Liu Y, Zhang H, Wang T, Diao R,
Jiang Z, Gui Y and Cai Z: Hsa-miR-125b suppresses bladder cancer
development by down-regulating oncogene SIRT7 and oncogenic long
non-coding RNA MALAT1. FEBS Lett. 587:3875–3882. 2013. View Article : Google Scholar
|
|
42
|
Cioffi M, Vallespinos-Serrano M, Trabulo
SM, Fernandez-Marcos PJ, Firment AN, Vazquez BN, Vieira CR, Mulero
F, Camara JA, Cronin UP, et al: MiR-93 controls adiposity via
inhibition of Sirt7 and Tbx3. Cell Rep. 12:1594–1605. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Vakhrusheva O, Smolka C, Gajawada P,
Kostin S, Boettger T, Kubin T, Braun T and Bober E: Sirt7 increases
stress resistance of cardiomyocytes and prevents apoptosis and
inflammatory cardiomyopathy in mice. Circ Res. 102:703–710. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kiran S, Oddi V and Ramakrishna G: Sirtuin
7 promotes cellular survival following genomic stress by
attenuation of DNA damage, SAPK activation and p53 response. Exp
Cell Res. 331:123–141. 2015. View Article : Google Scholar
|
